Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2
Takayuki Yoshida, Junya Kakegawa, Takayuki Yamaguchi, et al.
Oncotarget (2012) Vol. 3, Iss. 12, pp. 1533-1545
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Phenotypic screening in cancer drug discovery — past, present and future
John G. Moffat, Joachim Rudolph, David Bailey
Nature Reviews Drug Discovery (2014) Vol. 13, Iss. 8, pp. 588-602
Closed Access | Times Cited: 458
Phenotypic drug discovery: recent successes, lessons learned and new directions
Fabien Vincent, Arsenio Nueda, Jonathan Lee, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 12, pp. 899-914
Open Access | Times Cited: 191
Trametinib: First Global Approval
Cameron J. M. Wright, Paul L. McCormack
Drugs (2013) Vol. 73, Iss. 11, pp. 1245-1254
Closed Access | Times Cited: 179
Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
Nobuya Ishii, Naoki Harada, Eric W. Joseph, et al.
Cancer Research (2013) Vol. 73, Iss. 13, pp. 4050-4060
Open Access | Times Cited: 146
Structural basis for the action of the drug trametinib at KSR-bound MEK
Z.M. Khan, Alexander M. Real, William M. Marsiglia, et al.
Nature (2020) Vol. 588, Iss. 7838, pp. 509-514
Open Access | Times Cited: 122
Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use
Joost C.M. Uitdehaag, Jeroen A.D.M. de Roos, Antoon M. van Doornmalen, et al.
PLoS ONE (2014) Vol. 9, Iss. 3, pp. e92146-e92146
Open Access | Times Cited: 96
Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non–Small Cell Lung Cancers In Vitro and In Vivo
Zhen Tao, Justin M. Le Blanc, Chenguang Wang, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 1, pp. 122-133
Open Access | Times Cited: 86
Multiomic ALS signatures highlight subclusters and sex differences suggesting the MAPK pathway as therapeutic target
Lucas Caldi Gomes, Sonja Hänzelmann, Fabian Hausmann, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Allosteric MEK inhibitors act on BRAF/MEK complexes to block MEK activation
Gonzalo L. González‐Del Pino, Kunhua Li, Eunyoung Park, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 36
Open Access | Times Cited: 43
Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma
Robert S. McNeill, Demitra A. Canoutas, Timothy J. Stuhlmiller, et al.
Neuro-Oncology (2017) Vol. 19, Iss. 11, pp. 1469-1480
Open Access | Times Cited: 47
Selective anti-cancer agents as anti-aging drugs
Mikhail V. Blagosklonny
Cancer Biology & Therapy (2013) Vol. 14, Iss. 12, pp. 1092-1097
Open Access | Times Cited: 45
Targeting mutant NRAS signaling pathways in melanoma
Ha Linh Vu, Andrew E. Aplin
Pharmacological Research (2016) Vol. 107, pp. 111-116
Open Access | Times Cited: 44
Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF V600 Mutation
Sohita Dhillon
Targeted Oncology (2016) Vol. 11, Iss. 3, pp. 417-428
Closed Access | Times Cited: 42
Next-Generation Phenotypic Screening
Scott J. Warchal, Asier Unciti‐Broceta, Neil O. Carragher
Future Medicinal Chemistry (2016) Vol. 8, Iss. 11, pp. 1331-1347
Open Access | Times Cited: 41
Myeloid-Derived Suppressor Cells as a Regulator of Immunity in Organ Transplantation
Tsukasa Nakamura, Hidetaka Ushigome
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 8, pp. 2357-2357
Open Access | Times Cited: 38
DeepFLR facilitates false localization rate control in phosphoproteomics
Yu Zong, Yuxin Wang, Yi Yang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 11
Overcoming resistance to HER2 inhibitors through state-specific kinase binding
Chris J. Novotny, Sirkku Pollari, Jin H. Park, et al.
Nature Chemical Biology (2016) Vol. 12, Iss. 11, pp. 923-930
Open Access | Times Cited: 37
Drug–drug conjugates of MEK and Akt inhibitors for RAS-mutant cancers
Hikaru Fujita, Sachiko Arai, Hiroshi Arakawa, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 102, pp. 117674-117674
Closed Access | Times Cited: 3
Trametinib in the treatment of melanoma
Ramya Thota, Douglas B. Johnson, Jeffrey A. Sosman
Expert Opinion on Biological Therapy (2015) Vol. 15, Iss. 5, pp. 735-747
Open Access | Times Cited: 30
Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma
Elien De Thaye, Koen Van de Vijver, Joni Van der Meulen, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 25
Discovery of 3-benzyl-1,3-benzoxazine-2,4-dione analogues as allosteric mitogen-activated kinase kinase (MEK) inhibitors and anti-enterovirus 71 (EV71) agents
Jing Sun, Yan Niu, Chao Wang, et al.
Bioorganic & Medicinal Chemistry (2016) Vol. 24, Iss. 16, pp. 3472-3482
Closed Access | Times Cited: 24
Network Architecture Predisposes an Enzyme to Either Pharmacologic or Genetic Targeting
Karin Jensen, Christian B. Moyer, Kevin A. Janes
Cell Systems (2016) Vol. 2, Iss. 2, pp. 112-121
Open Access | Times Cited: 23
Ringing medicinal chemistry: The importance of 3-membered rings in drug discovery
Sahani Sandalima Uthumange, Angie Jun Hui Liew, Xavier Chee Wezen, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 116, pp. 117980-117980
Open Access | Times Cited: 2
Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation‐positive advanced cutaneous melanoma
Naoya Yamazaki, Arata Tsutsumida, Akira Takahashi, et al.
The Journal of Dermatology (2018) Vol. 45, Iss. 4, pp. 397-407
Open Access | Times Cited: 21
Disruption of Lipid Raft Function Increases Expression and Secretion of Monocyte Chemoattractant Protein-1 in 3T3-L1 Adipocytes
Juu‐Chin Lu, Yu‐Ting Chiang, Yu‐Chun Lin, et al.
PLoS ONE (2016) Vol. 11, Iss. 12, pp. e0169005-e0169005
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top